| Fiscal Month | 3月 |
|---|---|
| Established | 2001.3 |
| Listed | 2012.11 |
| Headquarters | 103-0023 東京都中央区日本橋本町3-8-3 日本橋ライフサイエンスビル3 |
| Phone | 03-6222-9547 |
| Employees | <26.3>連36名 単36名(48.5歳) [年]814万円 |
| URL | https://www.kidswellbio.com/ |
| Bank | みずほ,三菱Ｕ,北海道 |
| Supplier | ― |
| Customer | 千寿製薬 |
| Business Segments | バイオシミラー97,バイオ新薬-,細胞治療(再生医療)3 <26.3> |
| Foreign Ownership | 2.4% |
| Floating Shares | 17.4% |
| Investment Fund | 0.0% |
| Specific Shares | 32.5% |
| Market Cap Ranking | バイオテクノロジー 時価総額順位 26/53社 |
基本情報
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞（ＳＨＥＤ）用いた再生医療に力
特色【黒字化】加齢黄斑変性薬のバイオ後続品『ＧＢＳ‐007』は競合品の参入が打撃。ただ、バイオ後続品原薬等の供給価格改定と製造原価低減品への切り替えで粗利改善。開発費高水準だが営業黒字に転換。
【バイオ後続品】厚労省の助成金受け、他の２社と共同で秋田県に新製造施設設立。脳性麻痺の再生医療は持田製薬と共同で国内治験開始へと準備。継続前提に重要事象。
【時価総額増加倍率】3.07倍
27.3億円(2012.11.30)
【会社業績修正】上方2下方0
経常益÷期初会社予想‥倍
業績・指標・配当
| Period | Type | Revenue(M¥) | Op.Profit(M¥) | Net Income(M¥) | Op.Margin(%) | Net Margin(%) | EPS(¥) | Div(¥) |
|---|---|---|---|---|---|---|---|---|
| 会27.3予 | Fcst | 5,500 | 350 | ･･ | 6.4% | - | -- | （26.5.14発表）幅 |
| 単23.3 | Act | 2,776 | -550 | -657 | -19.8% | -23.7% | -20.8 | 0 |
| 単24.3 | Act | 2,431 (-12.4%) | -1,335 (-142.7%) | -1,422 (-116.4%) | -54.9% | -58.5% | -40.2 (-93.3%) | 0 |
| 連22.3 | Act | 1,569 (-35.5%) | -919 (+31.2%) | -535 (+62.4%) | -58.6% | -34.1% | -17.4 (+56.7%) | 0 |
| 連25.3 | Act | 5,082 (+223.9%) | 27 (+102.9%) | -21 (+96.1%) | 0.5% | -0.4% | -0.5 (+97.1%) | 0 |
| 連25.4～9 | Int | 3,276 | 215 | 60 | 6.6% | 1.8% | 1.3 | 0 |
| 連26.3 | Act | 6,589 (+29.7%) | -138 (-611.1%) | -413 (-1866.7%) | -2.1% | -6.3% | -8.5 (-1600.0%) | 0 |
| 連26.4～9予 | Fcst,Int | 2,800 (-14.5%) | 200 (-7.0%) | 50 (-16.7%) | 7.1% | 1.8% | 1 (-23.1%) | 0 |
| 連27.3予 | Fcst | 5,500 (-16.5%) | 350 (+353.6%) | 50 (+112.1%) | 6.4% | 0.9% | 1 (+111.8%) | 0 |
| 連28.3予 | Fcst | 5,500 (-16.5%) | 350 (+353.6%) | 50 (+112.1%) | 6.4% | 0.9% | 1 (+111.8%) | 0 |
| Period | 連26.3 |
|---|---|
| Total Assets (M¥) | 6,088 |
| Equity (M¥) | 1,605 |
| Equity Ratio | 26.4% |
| Capital (M¥) | 191 |
| Retained Earnings (M¥) | -1,241 |
| Interest Bearing Debt (M¥) | 2,549 |
| ROE | -28.1% 予3.1% |
| ROA | -6.8% 予0.8% |
| Operating CF (M¥) | -1,096 |
| Investing CF (M¥) | -12 |
| Financing CF (M¥) | 1,397 |
| Cash (M¥) | 3,294 |
| CapEx | ･･ 予･･ |
| Depreciation | 0 予･･ |
| R&D Expense | 767 予･･ |
| BPS (¥) | 32.4 / - |
| Period | Amount | Forecast |
|---|---|---|
| 21.3 | 0 | |
| 22.3 | 0 | |
| 23.3 | 0 | |
| 24.3 | 0 | |
| 25.3 | 0 | |
| 26.3 | 0 | |
| 27.3予 | 0 | Yes |
株主・役員構成
| Name | Shares (Ratio) |
|---|---|
| ノーリツ鋼機 | 947(19.0) |
| 江平文茂 | 200(4.0) |
| ＮＡＮＯ ＨＬＤ | 100(2.0) |
| 楽天証券 | 79(1.5) |
| 千寿製薬 | 55(1.1) |
| 野村信託銀行信託口２０５２２４１ | 47(0.9) |
| 北島義彦 | 44(0.8) |
| ＢＮＹ・ＧＣＭクライアントＪＰＲＤＩＳＧＦＥＡＣ | 44(0.8) |
| 津田謹誠 | 43(0.8) |
| 大友宏一 | 40(0.8) |
| Title | Name | Outside |
|---|---|---|
| 社長 | 紅林 伸也 | |
| 取締 | 栄木 憲和 | * |
| 取締 | 西岡 佐知子 | * |
| 常勤監査 | 菅原 治 | |
| 監査 | 森 正人 | * |
| 監査 | 品川 広志 | * |
No PDF available for the selected report.
この銘柄のEDINETレポートが見つかりませんでした。